GenSight Biologics S.A. (EPA:SIGHT)

Market Cap	26.92M +8.5%
Revenue (ttm)	652.00K -75.2%
Net Income	-12.04M
EPS	-0.08
Shares Out	234.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,580,289
Open	0.1050
Previous Close	0.1052
Day's Range	0.1018 - 0.1180
52-Week Range	0.0752 - 0.2390
Beta	0.64
Analysts	Buy
Price Target	0.31 (+170.04%)
Earnings Date	Sep 29, 2026

About GenSight Biologics

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 13
• Stock Exchange: Euronext Paris
• Ticker Symbol: SIGHT

Financial Performance

In 2025, GenSight Biologics's revenue was 652,000, a decrease of -75.16% compared to the previous year's 2.63 million. Losses were -12.04 million, -14.03% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for SIGHT stock is "Buy." The 12-month stock price target is €0.31, which is an increase of 170.04% from the latest price.

Price Target

€0.31

(170.04% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error